Document is current
Any future updates will be listed below
-
Authors
Thokala, Praveen
Duarte, Henrique https://orcid.org/0009-0007-6303-2631
Wright, Stuart
Husereau, Don
Durand-Zaleski, Isabelle
Lindgren, Peter
Postema, Roelien
Machnicki, Gerardo
Garrison, Louis
-
Funding
Funding for this research was provided by:
F. Hoffmann-La Roche
- License Information
-
More Information
Article History
Accepted: 6 October 2024
First Online: 17 December 2024
Declarations
:
: Henrique Duarte and Roelien Postema are full-time employees of Putnam Associates. Gerardo Machnicki is a full-time employee of F. Hoffmann-La Roche, Ltd. Praveen Thokala is the director of PT Health Economics Ltd and has been paid consultancy fees by Putnam/PHMR Ltd to advise on this study. He has also performed paid consultancy in the past with IQVIA, RTI-HS, Roche, Pfizer, Daiichi Sankyo, Exact Sciences, Abbvie, Novo Nordisk and Novartis. Stuart Wright is supported by a Wellcome Trust Early Career Award (226922/Z/23/Z). Don Husereau has received fees from F. Hoffmann-La Roche AG for unrelated projects. Isabelle Durand-Zaleski reports fees for speaking engagements and advisory board participation from BMS, Janssen, MSD, NovoNordisk and Hoffmann-La Roche AG for unrelated projects. Peter Lindgren reports institutional grants from AstraZeneca, Biogen, Jansen, MSD and Novartis and fees for speaking engagements and advisory board participation from Astellas, AstraZeneca, Biomarin, Daiichi Sankyo, Jansen, MSD, NovoNordisk, SOBI, Takeda and Vertex. Lou Garrison has received consulting and speaking fees unrelated to this project from Pfizer, Novartis Gene Therapy, Roche, Merck, J&J and BioMarin.
: Not applicable.
: Not applicable.
: Not applicable.
